CellMax Life
After years of research and clinical testing, we have developed non-invasive, accurate blood tests for early detection of cancer. By making cancer prevention routine, we enable everyone to take control of their own health. The more people take our breakthrough blood tests, the more lives we can save. Life over cancer.

CellMax Life

  • Publications
  • News Center
  • Company
  • Contact

Dr. Friedland on a Multimodal Screening Blood Test to Detect CRC

  • 0
Stephen Su
Friday, 17 February 2023 / Published in In the News

Feb 10, 2023 – Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

CellMax Life announced positive results from a multisite U.S. study that showed that its FirstSight blood test is highly accurate in detecting colorectal cancer and advanced adenomas. 

  • 0
Stephen Su
Friday, 27 January 2023 / Published in In the News

Jan 26, 2023 – CellMax Life announced positive results from a multisite U.S. study that showed that its FirstSight blood test is highly accurate in detecting colorectal cancer and advanced adenomas. 

Colorectal Cancer Detection Data from CellMax Life Bodes Well for Planned FDA Bid

  • 0
Stephen Su
Thursday, 19 January 2023 / Published in In the News

NEW YORK; Jan 19, 2023 – Cancer screening firm CellMax Life shared new data this week from a multi-site prospective study of its blood-based colorectal cancer detection assay, FirstSight.

CellMax Life’s Cancer Blood Test Designated FDA Breakthrough Device

  • 0
Stephen Su
Monday, 30 August 2021 / Published in In the News

FDANews; August 30, 2021 – Molecular diagnostics company CellMax Life’s FirstSight pre-cancer and cancer detection blood test has received the FDA’s Breakthrough Device designation.

In Brief This Week: Mount Sinai Health System, Sophia Genetics, CellMax Life, and More

  • 0
Stephen Su
Friday, 27 August 2021 / Published in In the News

GenomeWeb; August 27, 2021 – CellMax Life said this week that its FirstSight colorectal precancer and cancer detection blood test has received Breakthrough Device Designation from the US Food and Drug Administration.

CellMax Life gets FDA breakthrough device status for pre-cancer and cancer detection blood test

  • 0
Stephen Su
Thursday, 26 August 2021 / Published in In the News

Aug. 26, 2021 – The FirstSight blood test is a liquid biopsy, which will help measure colorectal neoplasia associated epithelial cells and DNA markers in human blood

Blood-Based Assay Sparks Hope for Improving Early Detection and Prevention of Colorectal Cancer

  • 0
Stephen Su
Wednesday, 27 January 2021 / Published in In the News
January 26, 2021 – A blood test for early detection of colorectal adenomas and cancer shows promise for improving survival and prevention of colorectal cancer (CRC) by enabling the stratification of patients for screening or post-polypectomy surveillance colonoscopy, according to a new study.

Blood test shows promise for early detection of colorectal adenomas

  • 0
Stephen Su
Monday, 18 January 2021 / Published in In the News

January 15, 2021 – A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results presented at Gastrointestinal Cancers Symposium.

Blood Test Detects Colon Cancer in Single-Center Study

  • 0
Stephen Su
Monday, 01 June 2020 / Published in In the News

MedScape | June 01, 2020 A blood test detected 11 of 11 cases of colorectal cancer in a study involving 354 patients, and also spotted a majority of cases — 40 out of 53 — in which participants had advanced adenomas, an investigator said.

Multimodal Blood Test Successfully Screens for Advanced CRC, Adenomas

  • 0
Stephen Su
Friday, 08 May 2020 / Published in In the News

OncLive | May 08, 2020 The multimodal FirstSightCRC blood test demonstrated higher sensitivity and specificity than standard screening protocols in detecting advanced adenomas and colorectal cancer (CRC), explained Shai Friedland, MD, who added that the noninvasive assay could lead to improved screening compliance.

  • 1
  • 2
  • 3
  • 4

Education

  • Our Science
  • Publications
  • News Center
  • Company
  • Contact

U.S. Headquarters

1271 Oakmead Parkway Sunnyvale, CA 94085
Phone: +1 650-564-3905

Taiwan Office

18F-1, No.3, Park Street Nangang Dist., Taipei City 115, Taiwan
+886-2-26558455 (Taiwan)

  • © 2023 CellMax Life
  • All Rights Reserved
  • Terms and Conditions
  • Privacy Policy
TOP